Genomic Sequencing May Help To Determine Prognosis in High-risk Prostate Cancer

Share this content:
Researchers obtained biopsies from 49 men with high-risk prostate cancer to determine genomic and T cell intratumoral heterogeneity.
Researchers obtained biopsies from 49 men with high-risk prostate cancer to determine genomic and T cell intratumoral heterogeneity.

Genomic testing and immunomodulation may help to improve outcomes among patients with prostate cancer, according to a study published in the Annals of Oncology.1

While low-risk prostate cancer carries a good prognosis, high-risk disease carries a 10-year cancer-specific survival rate of 20% to 25%. Correctly determining which patients have high-risk disease is important for sparing low-risk patients radical treatment.

To determine whether genomic testing can mark high-risk disease and reveal potential immunomodulatory targets, researchers obtained biopsies from 49 men with high-risk prostate cancer and conducted sequencing for genomic and T cell intratumoral heterogeneity.

The study (PROGENY; ClinicalTrials.gov Identifier: NCT02022371) included 23 men from the original 49 plus 2 additional patients who met the predefined criteria for genetic and T cell analysis. The researchers sequenced 79 tumor regions from the 25 included patients.

The researchers identified “4484 exonic somatic nucleotide variations (SNV) (3382 non-silent), of which 1962 were ubiquitous, 495 were shared, and 2027 were private.”

Extensive somatic copy number alteration (SCNA) heterogeneity was also found. Patients with metastatic hormone-naive disease had higher SCNA burden.

RELATED: Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Loss of mismatch repair (MMR) proteins was linked with intratumoral and intertumoral T cell heterogeneity; Wnt signaling was linked with immune suppression.

The authors concluded that genomic aberrations are “associated with altered patterns of immune infiltrate,” and further that Wnt may be a biomarker for immunomodulatory therapy.

Reference

  1. Linch M, Goh G, Hiley C, et al. Intratumoural evolutionary landscape of high risk prostate cancer: the PROGENY study of genomic and immune parameters. Ann Oncol. In press.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters